Clinical trialNCT03997968CompletedPhase 1/PHASE2Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

SponsorCyteir Therapeutics, Inc.Enrollment169Breast CancerCLLDLBCLFollicular LymphomaHead and Neck CancerMalignancy+9 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Markus Renschler, MD
Cyteir Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California San Francisco
San Francisco, California, United States
Stanford Comprehensive Cancer Center
Stanford, California, United States
Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
Florida Cancer Specialists and Research Institute
Sarasota, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
John Theurer Cancer Center at Humc
Hackensack, New Jersey, United States
Nyu Langone Health
New York, New York, United States
Oklahoma University-Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
University of Washington Seattle Cancer Center
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CYT-0851CYT-0851 in combination with capecitabineCYT-0851 in combination with gemcitabineCYT-0851 in combination with rituximab and bendamustine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Oct 2019
Primary completion: 30 Nov 2024
Completion: 20 Dec 2024
Last update posted: 24 Dec 2024
Registered enrollment: 169
Registry id: NCT03997968

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.